Last reviewed · How we verify
standardized drug treatment
At a glance
| Generic name | standardized drug treatment |
|---|---|
| Also known as | topiramate plus ibuprofen |
| Sponsor | Beijing Tiantan Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Acute Kidney Injury
- Hypotension
- Hospitalizations
- Septic shock
- Cellulitis
- Stroke
- Hyperkalemia
- Hyponatremia
- Hypertension
- Syncope
- Fall precipitating medical treatment
- Fluid overload
Key clinical trials
- A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events (NA)
- Thumb Base Osteoarthritis: Ultrasound-guided Platelet-rich Plasma Versus Placebo Injection (PHASE2)
- Effects of Different Caffeine Forms on Aerobic and Anaerobic Exercise Performance (NA)
- The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster (NA)
- Capsular Distension Versus Corticosteroid Injection in Adhesive Capsulitis (NA)
- Metabolome and Gut Microbiome Changes During Smoking Cessation in Long-term Drug Therapy in a Therapeutic Community (NA)
- Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre (NA)
- PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- standardized drug treatment CI brief — competitive landscape report
- standardized drug treatment updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI